SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-041189
Filing Date
2021-08-05
Accepted
2021-08-05 07:45:53
Documents
16
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-8k_20210805.htm   iXBRL 8-K 41929
2 EX-99.1 ntla-ex991_6.htm EX-99.1 97693
3 GRAPHIC g0yz0mjq5i0e000003.jpg GRAPHIC 341719
4 GRAPHIC g0yz0mjq5i0e000001.jpg GRAPHIC 114229
5 GRAPHIC g0yz0mjq5i0e000002.jpg GRAPHIC 756996
  Complete submission text file 0001564590-21-041189.txt   1953275

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ntla-20210805.xsd EX-101.SCH 5677
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20210805_lab.xml EX-101.LAB 19327
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20210805_pre.xml EX-101.PRE 11480
9 EXTRACTED XBRL INSTANCE DOCUMENT ntla-8k_20210805_htm.xml XML 3544
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 211146366
SIC: 2835 In Vitro & In Vivo Diagnostic Substances